Mdxhealth SA (NASDAQ: MDXH) presented data from the GPS-ProMPT study at the 41st Annual European Association of Urology Congress on March 13 in London. The study, conducted by investigators at the University of Oxford, evaluated the company's Genomic Prostate Score test in predicting treatment outcomes across multiple therapy approaches.

The GPS-ProMPT study analyzed 409 patients with localized or locally advanced prostate cancer over a median follow-up period of at least six years. Patients received active surveillance, radical prostatectomy, or radiotherapy treatments. The study found that the GPS test identified patients with favorable tumor biology even among clinically higher-risk groups.

Six-year freedom-from-failure outcomes showed 92% success rates in active surveillance patients and up to 100% among patients treated with surgery or radiotherapy, according to the company's announcement based on the press release.

Professor Freddie Hamdy from the University of Oxford presented the findings. "These results demonstrated that genomic insights from the GPS mdx test can identify patients with favorable tumor biology even among clinically higher-risk groups, helping clinicians better tailor treatment strategies and potentially avoid overtreatment," Hamdy stated.

The GPS test is a 17-gene expression assay performed on prostate biopsy tissue that evaluates tumor biology to estimate risks of adverse pathology, metastasis within 10 years, and disease progression. Mdxhealth announced in January 2026 that it initiated GPS testing in the UK ProtecT trial, described as the world's largest randomized clinical trial of treatment effectiveness in localized prostate cancer.

Mdxhealth focuses on urology precision diagnostics and provides molecular testing for prostate cancer and other urologic diseases.